Matthias P. A. Ebert
Research Subjects
Matthias P. A. Ebert has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Peter Malfertheiner
Department of Gastroenterology, Hepatology and Infectious Diseases; Institutes of
13 shared publications- Christoph Röcken
Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany
10 shared publications Jie Chen
Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University, Leipzigerstr. 44, D-39120 Magdeburg, Germany
5 shared publications- Jun Yu
Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
4 shared publications P Malfertheiner
Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany
4 shared publications- Alba Rocco
Department of Clinical Medicine and Surgery, Gastroenterology Unit, University Federico II, Naples, Italy
3 shared publications
Latest Publications
- 6 February 2008
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 46 (2) , 216-222
Neue Wege zur Früherkennung, Prognoseabschätzung und Therapie maligner Tumoren des Gastrointestinaltraktes
Gastrointestinale Tumoren sind mit einer weltweiten Zahl von ca. 2 Millionen Neuerkrankungen und 1,2 Millionen Sterbefällen pro Jahr die häufigsten malignen Tumoren des Menschen. Sie sind meistens Erkrankungen des Seniums. Bei kontinuierlich steigender Lebenserwartung in den westlichen Industrienationen nimmt ihre relative und absolute Häufigkeit kontinuierlich zu. Nur so ist zu erklären, warum das distale Magenkarzinom bei abnehmender Inzidenz eine steigende Prävalenz aufweist. Gastrointestinale Tumoren werden auch zukünftig ein immanentes klinisches und gesundheitsökonomisches Problem darstellen. Ihre Prognose ist oft schlecht, da sie meistens zu spät diagnostiziert werden und die therapeutischen Optionen dann nur noch eingeschränkt sind. Um diesen Problemen zu begegnen, müssen Strategien entwickelt werden, die eine Identifikation von Risikopatienten und Tumoren im Frühstadium erlauben und auf eine breitere Akzeptanz in der Bevölkerung stoßen. Es sollten prognostische und prädiktive Biomarker entwickelt und in der Klinik eingesetzt werden, die auch im Stande sind, eine Therapie in den verschiedenen Stadien einer Tumorerkrankung zu lenken. Tumours of the gastrointestinal tract are the single largest group of malignant tumours of humans accounting for approximately 2 million new cases and over 1.2 million deaths annually. They are most commonly a disease of the elderly, and their relative and absolute frequency will rise continuously due to an ageing population. This explains why the prevalence of gastric cancer increases in spite of a decreasing incidence. Gastrointestinal tumours will remain a major clinical and health economical challenge. The prognosis is often dismal. Most of these cancers are diagnosed in an advanced stage, which prohibits curative treatment and limits treatment options. In order to circumvent these problems, we need to develop strategies that allow identification of at-risk patients and tumours at an early stage, and raise the compliance in the general population for screening programmes. There is a great need in clinics for prognostic and predictive biomarkers that are able to tailor patient treatment at different stages of the disease.
- 6 February 2008
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 46 (2) , 216-222
Neue Wege zur Früherkennung, Prognoseabschätzung und Therapie maligner Tumoren des Gastrointestinaltraktes
Gastrointestinale Tumoren sind mit einer weltweiten Zahl von ca. 2 Millionen Neuerkrankungen und 1,2 Millionen Sterbefällen pro Jahr die häufigsten malignen Tumoren des Menschen. Sie sind meistens Erkrankungen des Seniums. Bei kontinuierlich steigender Lebenserwartung in den westlichen Industrienationen nimmt ihre relative und absolute Häufigkeit kontinuierlich zu. Nur so ist zu erklären, warum das distale Magenkarzinom bei abnehmender Inzidenz eine steigende Prävalenz aufweist. Gastrointestinale Tumoren werden auch zukünftig ein immanentes klinisches und gesundheitsökonomisches Problem darstellen. Ihre Prognose ist oft schlecht, da sie meistens zu spät diagnostiziert werden und die therapeutischen Optionen dann nur noch eingeschränkt sind. Um diesen Problemen zu begegnen, müssen Strategien entwickelt werden, die eine Identifikation von Risikopatienten und Tumoren im Frühstadium erlauben und auf eine breitere Akzeptanz in der Bevölkerung stoßen. Es sollten prognostische und prädiktive Biomarker entwickelt und in der Klinik eingesetzt werden, die auch im Stande sind, eine Therapie in den verschiedenen Stadien einer Tumorerkrankung zu lenken. Tumours of the gastrointestinal tract are the single largest group of malignant tumours of humans accounting for approximately 2 million new cases and over 1.2 million deaths annually. They are most commonly a disease of the elderly, and their relative and absolute frequency will rise continuously due to an ageing population. This explains why the prevalence of gastric cancer increases in spite of a decreasing incidence. Gastrointestinal tumours will remain a major clinical and health economical challenge. The prognosis is often dismal. Most of these cancers are diagnosed in an advanced stage, which prohibits curative treatment and limits treatment options. In order to circumvent these problems, we need to develop strategies that allow identification of at-risk patients and tumours at an early stage, and raise the compliance in the general population for screening programmes. There is a great need in clinics for prognostic and predictive biomarkers that are able to tailor patient treatment at different stages of the disease.
- Open Access
- 1 December 2005
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 14 (12) , 2987-2989
The Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism Is Linked to Early Gastric Cancer
The insertion/deletion polymorphism of the angiotensin I–converting enzyme (ACE) gene has recently been linked to the pathogenesis and progression of human cancers. Using genomic DNA from 88 patients with early gastric cancer confined either to mucosa (pT1a) or submucosa (pT1b), we assessed the insertion (I) and deletion (D) polymorphism by PCR analysis and compared it with a large noncancer control population (n = 145). In the noncancer control group, the II genotype was observed in 33 (23%) individuals, whereas the ID and DD genotypes were found in 72 (50%) and 40 (27%) individuals, respectively. Interestingly, in the cancer group, we found the II genotype in six (7%) patients and the ID genotype in 46 (52%) individuals, whereas the DD genotype was observed in 36 (41%) individuals (P = 0.0034). Accordingly, the odds ratio for the II genotype was 0.20 [95% confidence interval (95% CI), 0.08-0.54; P = 0.009] and 0.55 for the ID/II genotype (95% CI, 0.31-0.96; P = 0.044) using the high-activity genotype DD as the reference category. No correlation was found among tumor type, tumor stage, the presence of Helicobacter pylori, and the ACE genotype. Our study provides further evidence that the ACE insertion/deletion gene polymorphism may be linked to the development of early gastric cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2987–9)
- 1 December 2005
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 14 (12) , 2987-2989
Open AccessThe Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism Is Linked to Early Gastric Cancer
The insertion/deletion polymorphism of the angiotensin I–converting enzyme (ACE) gene has recently been linked to the pathogenesis and progression of human cancers. Using genomic DNA from 88 patients with early gastric cancer confined either to mucosa (pT1a) or submucosa (pT1b), we assessed the insertion (I) and deletion (D) polymorphism by PCR analysis and compared it with a large noncancer control population (n = 145). In the noncancer control group, the II genotype was observed in 33 (23%) individuals, whereas the ID and DD genotypes were found in 72 (50%) and 40 (27%) individuals, respectively. Interestingly, in the cancer group, we found the II genotype in six (7%) patients and the ID genotype in 46 (52%) individuals, whereas the DD genotype was observed in 36 (41%) individuals (P = 0.0034). Accordingly, the odds ratio for the II genotype was 0.20 [95% confidence interval (95% CI), 0.08-0.54; P = 0.009] and 0.55 for the ID/II genotype (95% CI, 0.31-0.96; P = 0.044) using the high-activity genotype DD as the reference category. No correlation was found among tumor type, tumor stage, the presence of Helicobacter pylori, and the ACE genotype. Our study provides further evidence that the ACE insertion/deletion gene polymorphism may be linked to the development of early gastric cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2987–9)
- Open Access
Expression of carbonic anhydrase 9 at the invasion front of gastric cancers
Background: Carbonic anhydrase IX (MN/Ca9) catalyses the reversible metabolism of carbon dioxide to carbonic acid and has also been linked to malignant transformation and hypoxia in various cancers. Aims: To assess the expression and biological role of Ca9 in gastric cancer. Methods: Using gastric cancer cell lines and tissues, we studied expression of Ca9 by western blot analysis, immunohistochemistry, and polymerase chain reaction. Biological changes after Ca9 transfection and after treatment with 5′-azadeoxycytidine were also analysed in cancer cell lines. Results: Non-cancerous tissues strongly expressed Ca9 with membranous localisation. In contrast, Ca9 expression was frequently lost in gastric cancers (pConclusions: A subgroup of gastric cancers retain Ca9 expression in cancer cells at the invasion front. While loss of Ca9 expression is regulated in part by methylation, re-expression of Ca9 is associated with increased invasion, supporting the hypothesis that increased Ca9 expression may contribute to invasion and thus advanced disease and tumour progression in a subset of gastric cancers.
Open AccessExpression of carbonic anhydrase 9 at the invasion front of gastric cancers
Background: Carbonic anhydrase IX (MN/Ca9) catalyses the reversible metabolism of carbon dioxide to carbonic acid and has also been linked to malignant transformation and hypoxia in various cancers. Aims: To assess the expression and biological role of Ca9 in gastric cancer. Methods: Using gastric cancer cell lines and tissues, we studied expression of Ca9 by western blot analysis, immunohistochemistry, and polymerase chain reaction. Biological changes after Ca9 transfection and after treatment with 5′-azadeoxycytidine were also analysed in cancer cell lines. Results: Non-cancerous tissues strongly expressed Ca9 with membranous localisation. In contrast, Ca9 expression was frequently lost in gastric cancers (pConclusions: A subgroup of gastric cancers retain Ca9 expression in cancer cells at the invasion front. While loss of Ca9 expression is regulated in part by methylation, re-expression of Ca9 is associated with increased invasion, supporting the hypothesis that increased Ca9 expression may contribute to invasion and thus advanced disease and tumour progression in a subset of gastric cancers.
- 11 May 2005
- Published by Elsevier in Cancer Letters
- Vol. 233 (2) , 328-337
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression
- 11 May 2005
- Published by Elsevier in Cancer Letters
- Vol. 233 (2) , 328-337
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression
- 4 March 2005
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 4 (2) , 586-590
Identification of the Thrombin Light Chain A as the Single Best Mass for Differentiation of Gastric Cancer Patients from Individuals with Dyspepsia by Proteome Analysis
Gastric cancer mortality is second only to lung cancer, and its prognosis is dismal. Using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry, we previously identified a single best mass, which could separate gastric cancer from patients without cancer, with a sensitivity of 89.9% and a specificity of 90%. Using protein liquid chromatography systems with various chromatography media and MS/MS analysis, we were able to identify thrombin light chain A, a proteolytic fragment of prothrombin, as the single best mass for early detection of gastric cancer patients. These findings indicate that disturbances in the coagulation-system are early events in gastric cancer biology and that a decrease or loss of thrombin light chain A, which we termed negative serum protein profiling, may contribute to the diagnosis of cancer patients. Keywords: gastric • carcinoma • stomach • SELDI • biomarker • thrombin • thrombosis • diagnosis
- 4 March 2005
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 4 (2) , 586-590
Identification of the Thrombin Light Chain A as the Single Best Mass for Differentiation of Gastric Cancer Patients from Individuals with Dyspepsia by Proteome Analysis
Gastric cancer mortality is second only to lung cancer, and its prognosis is dismal. Using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry, we previously identified a single best mass, which could separate gastric cancer from patients without cancer, with a sensitivity of 89.9% and a specificity of 90%. Using protein liquid chromatography systems with various chromatography media and MS/MS analysis, we were able to identify thrombin light chain A, a proteolytic fragment of prothrombin, as the single best mass for early detection of gastric cancer patients. These findings indicate that disturbances in the coagulation-system are early events in gastric cancer biology and that a decrease or loss of thrombin light chain A, which we termed negative serum protein profiling, may contribute to the diagnosis of cancer patients. Keywords: gastric • carcinoma • stomach • SELDI • biomarker • thrombin • thrombosis • diagnosis
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 26 (1) , 37-43
Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis
APC (adenomatous polyposis coli) promoter methylation has been linked to the early development of colorectal cancers. However, the role of APC methylation and its effect on protein expression in colon cancer metastasis is largely unknown. In this study, we investigated APC promoter methylation by Methylight analysis and analysed the APC protein levels by immunohistochemistry and western blot analysis in 24 liver metastasis and 39 primary colorectal cancers. Promoter methylation of the APC gene was found to be a frequent event in liver metastasis (10/24) and significantly more frequent compared with primary colorectal cancer (7/39, P = 0.047). APC methylation was not found in 14 matched normal colon tissues. APC protein was detected in the cytoplasm of primary and metastatic cancer cells and non-tumorous colon epithelium. By western blot analysis, APC protein levels were found to be decreased in primary tumour tissues compared with the normal colon mucosa. In contrast, APC protein levels were not decreased in the cancer cells that had metastasized to the liver. APC protein levels were independent of the presence of APC promoter methylation or gene mutations. In summary, APC promoter methylation is a frequent epigenetic alteration in colorectal cancer metastasis. However, we observed no significant association between APC promoter methylation or gene mutation and APC protein expression in colorectal metastasis. Therefore, metastatic cancer cells seem to harbour a heterogenous genetic and epigenetic background, in which cancer cells may exhibit APC promoter methylation that is independent of APC expression.
- 1 January 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 26 (1) , 37-43
Open AccessMolecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis
APC (adenomatous polyposis coli) promoter methylation has been linked to the early development of colorectal cancers. However, the role of APC methylation and its effect on protein expression in colon cancer metastasis is largely unknown. In this study, we investigated APC promoter methylation by Methylight analysis and analysed the APC protein levels by immunohistochemistry and western blot analysis in 24 liver metastasis and 39 primary colorectal cancers. Promoter methylation of the APC gene was found to be a frequent event in liver metastasis (10/24) and significantly more frequent compared with primary colorectal cancer (7/39, P = 0.047). APC methylation was not found in 14 matched normal colon tissues. APC protein was detected in the cytoplasm of primary and metastatic cancer cells and non-tumorous colon epithelium. By western blot analysis, APC protein levels were found to be decreased in primary tumour tissues compared with the normal colon mucosa. In contrast, APC protein levels were not decreased in the cancer cells that had metastasized to the liver. APC protein levels were independent of the presence of APC promoter methylation or gene mutations. In summary, APC promoter methylation is a frequent epigenetic alteration in colorectal cancer metastasis. However, we observed no significant association between APC promoter methylation or gene mutation and APC protein expression in colorectal metastasis. Therefore, metastatic cancer cells seem to harbour a heterogenous genetic and epigenetic background, in which cancer cells may exhibit APC promoter methylation that is independent of APC expression.
- 1 December 2004
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 21 (5) , 389-397
Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine
- 1 December 2004
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 21 (5) , 389-397
Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine
- 20 October 2004
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 3 (6) , 1261-1266
Identification of Gastric Cancer Patients by Serum Protein Profiling
Using surface-enhanced laser desorption ionization mass spectrometry (SELDI/TOF−MS) and ProteinChip technology, coupled with a pattern-matching algorithm and serum samples, we screened for protein patterns to differentiate gastric cancer patients from noncancer patients. A classifier ensemble, consisting of 50 decision trees, correctly classified all gastric cancers and all controls of a training set (100% sensitivity and 100% specificity). Eight of 9 stage I gastric cancers (88.9% sensitivity for stage I) were correctly classified. In addition, 28 sera from gastric cancer patients taken in different hospitals were correctly classified (100% sensitivity). Furthermore, all 11 control sera obtained from patients without gastric cancer (100% specificity) were classified correctly and 29 of 30 healthy blood-donors were classified as noncancerous. ProteinChip technology in conjunction with bioinformatics allows the highly sensitive and specific recognition of gastric cancer patients. Keywords: Proteomics • diagnosis • stomach • SELDI
- 20 October 2004
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 3 (6) , 1261-1266
Identification of Gastric Cancer Patients by Serum Protein Profiling
Using surface-enhanced laser desorption ionization mass spectrometry (SELDI/TOF−MS) and ProteinChip technology, coupled with a pattern-matching algorithm and serum samples, we screened for protein patterns to differentiate gastric cancer patients from noncancer patients. A classifier ensemble, consisting of 50 decision trees, correctly classified all gastric cancers and all controls of a training set (100% sensitivity and 100% specificity). Eight of 9 stage I gastric cancers (88.9% sensitivity for stage I) were correctly classified. In addition, 28 sera from gastric cancer patients taken in different hospitals were correctly classified (100% sensitivity). Furthermore, all 11 control sera obtained from patients without gastric cancer (100% specificity) were classified correctly and 29 of 30 healthy blood-donors were classified as noncancerous. ProteinChip technology in conjunction with bioinformatics allows the highly sensitive and specific recognition of gastric cancer patients. Keywords: Proteomics • diagnosis • stomach • SELDI
- 1 September 2003
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 129 (9) , 493-497
Expression of caveolin-1 in gastrointestinal and extraintestinal cancers
Caveolae are uniform vesicular invaginations of the cell membrane. Caveolin-1 is responsible for the formation of caveolae and plays a key role in membrane traffic and signal transduction. The contribution of caveolin-1 to carcinogenesis has been widely investigated; however, the expression pattern of caveolin-1 is controversial both in gastrointestinal and extraintestinal cancers. Most of the results based on cancer cell line experiments suggest that caveolin-1 might act as a tumor-suppressor gene. On the contrary, several studies on the expression of caveolin-1 in tumor tissues indicate a possible tumor-promoting effect of caveolin-1. In this article we summarize the divergent results of caveolin-1 expression in gastrointestinal and extraintestinal cancer regarding possible future therapeutic implications.
- 1 September 2003
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 129 (9) , 493-497
Expression of caveolin-1 in gastrointestinal and extraintestinal cancers
Caveolae are uniform vesicular invaginations of the cell membrane. Caveolin-1 is responsible for the formation of caveolae and plays a key role in membrane traffic and signal transduction. The contribution of caveolin-1 to carcinogenesis has been widely investigated; however, the expression pattern of caveolin-1 is controversial both in gastrointestinal and extraintestinal cancers. Most of the results based on cancer cell line experiments suggest that caveolin-1 might act as a tumor-suppressor gene. On the contrary, several studies on the expression of caveolin-1 in tumor tissues indicate a possible tumor-promoting effect of caveolin-1. In this article we summarize the divergent results of caveolin-1 expression in gastrointestinal and extraintestinal cancer regarding possible future therapeutic implications.